Literature DB >> 6127134

Nadolol and potassium iodide in combination in the surgical treatment of thyrotoxicosis.

N R Peden, A Gunn, M C Browning, J Crooks, A L Forrest, W F Hamilton, T E Isles.   

Abstract

With the two aims of rapidly reducing circulating thyroid hormone levels and controlling the symptoms of thyrotoxicosis, we have prepared 17 thyrotoxic patients for subtotal thyroidectomy, using a combination of potassium iodide administered for 10 days and the long acting beta-adrenoceptor antagonist nadolol. All 17 patients had normal serum thyroxine levels after 10 days of such treatment although 10 still showed elevation of serum tri-iodothyronine and considerable elevation in the most severely toxic patient. All patients were, however, clinically euthyroid preoperatively. Nadolol was administered once daily, hence avoiding the problems of drug administration in the immediate postoperative period, and plasma nadolol concentrations were high throughout the perioperative period. Serum thyroxine and tri-iodothyronine levels were significantly lower and reverse tri-iodothyronine levels higher 24 h postoperatively than before operation. All patients remained stable throughout the perioperative period. We conclude that this regimen has a number of advantages in the preparation of patients for thyroidectomy, in reducing the degree of thyrotoxicosis, in convenience of drug administration and in ensuring adequate circulating concentrations of beta-adrenoceptor antagonist whilst still retaining a relatively short preoperative phase of drug treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127134     DOI: 10.1002/bjs.1800691103

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  2 in total

1.  Thyroid surgery for Graves' disease.

Authors:  A D Toft
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

Review 2.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.